Every 8-K that Damora Therapeutics, Inc. (DMRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DMRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMRA filings page.
Damora Therapeutics, Inc. completed a redomestication from Delaware to the Cayman Islands effective July 16, 2026, via a Plan of Conversion. The company now exists as a Cayman Islands exempted company while continuing to operate as Damora Therapeutics, Inc. and to be treated as a U.S. corporation for federal tax purposes.
Each outstanding share of Delaware common stock automatically converted into one ordinary share, par value $0.00001 per share, of the Cayman company, and each preferred share converted into the corresponding Cayman preferred share. Options, rights and restricted stock units now relate to the same number of Cayman ordinary shares. Nasdaq trading continues under the symbol DMRA, with a new CUSIP G2646Y104 from the open on July 20, 2026, without trading interruption.
The company’s internal affairs and shareholder rights are now governed by Cayman law and the Cayman Memorandum and Articles of Association, and certain shareholder rights changed as described in the prior proxy statement. Business, management, obligations, assets, liabilities, material contracts, SEC reporting status and accounting treatment are stated to be unaffected. On July 16, 2026, Damora also entered into new indemnification agreements with all directors and executive officers, providing indemnification and advancement of expenses subject to specified terms.
Damora Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected Michael Landsittel and Cameron Turtle, D.Phil, as Class III directors to serve until the 2029 annual meeting. An advisory vote approved the compensation of the company’s named executive officers, and stockholders indicated a preference to hold this Say-on-Pay vote every year. Stockholders also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. A quorum was present, with 55,009,938 shares represented out of 60,303,212 shares outstanding on the record date.
Damora Therapeutics, Inc. announced a finance leadership change. The Board determined that, effective May 1, 2026, Lori Firmani will cease serving as Chief Financial Officer, principal financial officer, and principal accounting officer. Her departure benefits will follow the company’s Executive Separation Benefits Plan, with base salary continuation and pro-rated target bonus paid in a single lump sum, a $6,000 health savings account contribution, and full acceleration of all outstanding equity awards, subject to her signing a separation agreement and release.
The Board appointed Brian Burkavage, currently Senior Vice President, Finance, to serve as principal financial officer and principal accounting officer effective at the same time. Burkavage, age 43, has held senior finance roles at IO Biotech, Passage Bio, and Aclaris Therapeutics and previously spent 11 years at Ernst & Young. He will enter into Damora’s standard executive indemnification agreement, and the company states he has no disclosable related-party transactions or family relationships with directors or executives.
Damora Therapeutics, Inc. changed its independent auditor. On April 17, 2026, the Audit Committee dismissed EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm and appointed Ernst & Young LLP (EY US) effective immediately.
EY Denmark’s reports on the Company’s financial statements for 2025 and 2024 contained no adverse or qualified opinions, although the 2024 report included an explanatory paragraph about the Company’s ability to continue as a going concern. The Company reports no disagreements or reportable events with EY Denmark and states that it did not consult EY US on accounting or auditing matters before the engagement.
Damora Therapeutics announced a major leadership and board refresh. The Board appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026, and she will also join the Board. Her offer includes a $695,000 base salary, a target bonus equal to 55% of salary, 500,000 restricted stock units vesting over four years, and options to purchase 1,500,000 shares vesting over four years, with enhanced severance and accelerated vesting protections around a change in control.
Current COO Sherwin Sattarzadeh will step down as principal executive officer but remain Chief Operating Officer. Directors Amit Munshi, Carl Goldfischer and Jayson Dallas resigned, with their equity awards fully accelerated, and the Board size was reduced from seven to six. Michael Landsittel and Cameron Turtle were appointed as Class III directors and will receive options under the 2026 Equity Incentive Plan, while Peter Harwin was named Board chair. Damora also updated compensation and severance terms for General Counsel Garrett Winslow, including a $440,000 salary, a 40% target bonus and options for 250,000 shares.